الاتحاد الأوروبي -
الإستونية -
EMA (European Medicines Agency)
daurismo
pfizer europe ma eeig - glasdegib maleate - leukeemia, müeloidne, äge - antineoplastilised ained - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
الاتحاد الأوروبي -
الإستونية -
EMA (European Medicines Agency)
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastilised ained - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
أستونيا -
الإستونية -
Ravimiamet
sotorasib (amg 510) õhukese polümeerikattega tablett
amgen inc. - sotorasiib - õhukese polümeerikattega tablett - 120mg 120tk
أستونيا -
الإستونية -
Ravimiamet
pevonedistat (tak-924/mln4924) infusioonilahuse kontsentraat
takeda development center americas, inc. - pevonedistaat - infusioonilahuse kontsentraat - 10mg 1ml 5ml 1tk
الاتحاد الأوروبي -
الإستونية -
EMA (European Medicines Agency)
nexpovio
stemline therapeutics b.v. - selinexor - mitu müeloomit - antineoplastilised ained - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
الاتحاد الأوروبي -
الإستونية -
EMA (European Medicines Agency)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastilised ained - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
الاتحاد الأوروبي -
الإستونية -
EMA (European Medicines Agency)
rubraca
pharmaand gmbh - rucaparib camsylate - munasarjade kasvajad - antineoplastilised ained - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca on näidustatud monotherapy hooldus-ravi täiskasvanud patsientidel, kellel on plaatina-tundlik taastekkinud kõrge kvaliteediga epiteeli munasarja -, munajuha-või esmase peritoneaaldialüüsi vähi, kes on vastuseks (täielik või osaline) platinum põhineva keemiaravi.